The modified Glasgow Prognostic Scores as a predictor in diffuse large B cell lymphoma treated with R-CHOP regimen

Yundeok Kim; Soo Jeong Kim; Dohyu Hwang; Jieun Jang; Shin Young Hyun; Yu Ri Kim; Jin Seok Kim; Yoo Hong Min; June Won Cheong

doi:10.3349/ymj.2014.55.6.1568

The modified Glasgow Prognostic Scores as a predictor in diffuse large B cell lymphoma treated with R-CHOP regimen

Yundeok Kim, Soo Jeong Kim, Dohyu Hwang, Jieun Jang, Shin Young Hyun, Yu Ri Kim, Jin Seok Kim, Yoo Hong Min, June Won Cheong

Department of Internal Medicine

Research output: Contribution to journal › Article

16 Citations (Scopus)

Abstract

Purpose: The modified Glasgow Prognostic Score (mGPS) consisting of serum C-reactive protein and albumin levels, shows significant prognostic value in several types of tumors. We evaluated the prognostic significance of mGPS in 285 patients with diffuse large B cell lymphoma (DLBCL), retrospectively.

Materials and Methods: According to mGPS classification, 204 patients (71.5%) had an mGPS of 0, 57 (20%) had an mGPS of 1, and 24 (8.5%) had an mGPS of 2.

Results: Our study found that high mGPS were associated with poor prognostic factors including older age, extranodal involvement, advanced disease stage, unfavorable International Prognostic Index scores, and the presence of B symptoms. The complete response (CR) rate after 3 cycles of R-CHOP chemotherapy was higher in patients with mGPS of 0 (53.8%) compared to those with mGPS of 1 (33.3%) or 2 (25.0%) (p=0.001). Patients with mGPS of 0 had significantly better overall survival (OS) than those with mGPS=1 and those with mGPS=2 (p=0.036). Multivariate analyses revealed that the GPS score was a prognostic factor for the CR rate of 3 cycle R-CHOP therapy (p=0.044) as well as OS (p=0.037).

Conclusion: mGPS can be considered a potential prognostic factor that may predict early responses to R-CHOP therapy in DLBCL patients.

Original language	English
Pages (from-to)	1568-1575
Number of pages	8
Journal	Yonsei medical journal
Volume	55
Issue number	6
DOIs	https://doi.org/10.3349/ymj.2014.55.6.1568
Publication status	Published - 2014 Nov 1

All Science Journal Classification (ASJC) codes

Medicine(all)

Access to Document

10.3349/ymj.2014.55.6.1568

Fingerprint Dive into the research topics of 'The modified Glasgow Prognostic Scores as a predictor in diffuse large B cell lymphoma treated with R-CHOP regimen'. Together they form a unique fingerprint.

Cite this

Kim, Y., Kim, S. J., Hwang, D., Jang, J., Hyun, S. Y., Kim, Y. R., Kim, J. S., Min, Y. H., & Cheong, J. W. (2014). The modified Glasgow Prognostic Scores as a predictor in diffuse large B cell lymphoma treated with R-CHOP regimen. Yonsei medical journal, 55(6), 1568-1575. https://doi.org/10.3349/ymj.2014.55.6.1568

@article{209b8ffed33a4ccca3e69628889bc3e2,

title = "The modified Glasgow Prognostic Scores as a predictor in diffuse large B cell lymphoma treated with R-CHOP regimen",

abstract = "Purpose: The modified Glasgow Prognostic Score (mGPS) consisting of serum C-reactive protein and albumin levels, shows significant prognostic value in several types of tumors. We evaluated the prognostic significance of mGPS in 285 patients with diffuse large B cell lymphoma (DLBCL), retrospectively.Materials and Methods: According to mGPS classification, 204 patients (71.5%) had an mGPS of 0, 57 (20%) had an mGPS of 1, and 24 (8.5%) had an mGPS of 2.Results: Our study found that high mGPS were associated with poor prognostic factors including older age, extranodal involvement, advanced disease stage, unfavorable International Prognostic Index scores, and the presence of B symptoms. The complete response (CR) rate after 3 cycles of R-CHOP chemotherapy was higher in patients with mGPS of 0 (53.8%) compared to those with mGPS of 1 (33.3%) or 2 (25.0%) (p=0.001). Patients with mGPS of 0 had significantly better overall survival (OS) than those with mGPS=1 and those with mGPS=2 (p=0.036). Multivariate analyses revealed that the GPS score was a prognostic factor for the CR rate of 3 cycle R-CHOP therapy (p=0.044) as well as OS (p=0.037).Conclusion: mGPS can be considered a potential prognostic factor that may predict early responses to R-CHOP therapy in DLBCL patients.",

author = "Yundeok Kim and Kim, {Soo Jeong} and Dohyu Hwang and Jieun Jang and Hyun, {Shin Young} and Kim, {Yu Ri} and Kim, {Jin Seok} and Min, {Yoo Hong} and Cheong, {June Won}",

year = "2014",

month = nov,

day = "1",

doi = "10.3349/ymj.2014.55.6.1568",

language = "English",

volume = "55",

pages = "1568--1575",

journal = "Yonsei Medical Journal",

issn = "0513-5796",

publisher = "Yonsei University College of Medicine",

number = "6",

}

The modified Glasgow Prognostic Scores as a predictor in diffuse large B cell lymphoma treated with R-CHOP regimen. / Kim, Yundeok; Kim, Soo Jeong; Hwang, Dohyu; Jang, Jieun; Hyun, Shin Young; Kim, Yu Ri; Kim, Jin Seok; Min, Yoo Hong; Cheong, June Won.

In: Yonsei medical journal, Vol. 55, No. 6, 01.11.2014, p. 1568-1575.

Research output: Contribution to journal › Article

TY - JOUR

T1 - The modified Glasgow Prognostic Scores as a predictor in diffuse large B cell lymphoma treated with R-CHOP regimen

AU - Kim, Yundeok

AU - Kim, Soo Jeong

AU - Hwang, Dohyu

AU - Jang, Jieun

AU - Hyun, Shin Young

AU - Kim, Yu Ri

AU - Kim, Jin Seok

AU - Min, Yoo Hong

AU - Cheong, June Won

PY - 2014/11/1

Y1 - 2014/11/1

N2 - Purpose: The modified Glasgow Prognostic Score (mGPS) consisting of serum C-reactive protein and albumin levels, shows significant prognostic value in several types of tumors. We evaluated the prognostic significance of mGPS in 285 patients with diffuse large B cell lymphoma (DLBCL), retrospectively.Materials and Methods: According to mGPS classification, 204 patients (71.5%) had an mGPS of 0, 57 (20%) had an mGPS of 1, and 24 (8.5%) had an mGPS of 2.Results: Our study found that high mGPS were associated with poor prognostic factors including older age, extranodal involvement, advanced disease stage, unfavorable International Prognostic Index scores, and the presence of B symptoms. The complete response (CR) rate after 3 cycles of R-CHOP chemotherapy was higher in patients with mGPS of 0 (53.8%) compared to those with mGPS of 1 (33.3%) or 2 (25.0%) (p=0.001). Patients with mGPS of 0 had significantly better overall survival (OS) than those with mGPS=1 and those with mGPS=2 (p=0.036). Multivariate analyses revealed that the GPS score was a prognostic factor for the CR rate of 3 cycle R-CHOP therapy (p=0.044) as well as OS (p=0.037).Conclusion: mGPS can be considered a potential prognostic factor that may predict early responses to R-CHOP therapy in DLBCL patients.

AB - Purpose: The modified Glasgow Prognostic Score (mGPS) consisting of serum C-reactive protein and albumin levels, shows significant prognostic value in several types of tumors. We evaluated the prognostic significance of mGPS in 285 patients with diffuse large B cell lymphoma (DLBCL), retrospectively.Materials and Methods: According to mGPS classification, 204 patients (71.5%) had an mGPS of 0, 57 (20%) had an mGPS of 1, and 24 (8.5%) had an mGPS of 2.Results: Our study found that high mGPS were associated with poor prognostic factors including older age, extranodal involvement, advanced disease stage, unfavorable International Prognostic Index scores, and the presence of B symptoms. The complete response (CR) rate after 3 cycles of R-CHOP chemotherapy was higher in patients with mGPS of 0 (53.8%) compared to those with mGPS of 1 (33.3%) or 2 (25.0%) (p=0.001). Patients with mGPS of 0 had significantly better overall survival (OS) than those with mGPS=1 and those with mGPS=2 (p=0.036). Multivariate analyses revealed that the GPS score was a prognostic factor for the CR rate of 3 cycle R-CHOP therapy (p=0.044) as well as OS (p=0.037).Conclusion: mGPS can be considered a potential prognostic factor that may predict early responses to R-CHOP therapy in DLBCL patients.

UR - http://www.scopus.com/inward/record.url?scp=84908244567&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908244567&partnerID=8YFLogxK

U2 - 10.3349/ymj.2014.55.6.1568

DO - 10.3349/ymj.2014.55.6.1568

M3 - Article

C2 - 25323893

AN - SCOPUS:84908244567

VL - 55

SP - 1568

EP - 1575

JO - Yonsei Medical Journal

JF - Yonsei Medical Journal

SN - 0513-5796

IS - 6

ER -